Haigan
Online ISSN : 1348-9992
Print ISSN : 0386-9628
ISSN-L : 0386-9628
Invited Review Article
Current Treatment Strategies for Lung Cancer Combined with Interstitial Lung Diseases
Toshihiko Sato
Author information
JOURNAL OPEN ACCESS

2017 Volume 57 Issue 7 Pages 819-825

Details
Abstract

Interstitial lung diseases (ILDs) frequently occur with lung cancer. Anticancer therapy may provoke the acute exacerbation of interstitial pneumonia (AE), which is a potentially fatal complication. After Yoshimura et al. proposed the diagnostic criteria of AE for therapeutic interventions, the importance of this serious complication became widely understood. ILDs themselves are well-characterized as an entity, and advances in research have been made concerning their outcomes and prognoses. The poor prognosis associated with ILDs is widely recognized. Currently, the risk of severe AE is present in all anticancer therapies (including surgical resection, chemotherapy, and radiation therapy), and a more cautious approach is required. As research on the AE incidence, risk factors, and treatment outcomes continues to progress, oncologists have entered a new phase. With the accumulation of knowledge on preventive care, there is a trend toward advancements in treatment with evidence-based precautions. In light of such trends, this article outlines the recent anticancer therapies for lung cancer patients with ILDs.

Content from these authors
© 2017 by The Japan Lung Cancer Society
Next article
feedback
Top